Biosimilar Sponsors Offer Advisory Committee Primer
Executive Summary
Extrapolation, uncertainty could prove important when the Oncologic Drugs Advisory Committee considers Sandoz’s filgrastim biosimilar on Jan. 7.
You may also be interested in...
Lessons From The First Biosimilar MAb Launch In Europe
Physicians appear more willing to prescribe Hospira’s Inflectra, a biosimilar version of J&J’s Remicade, to new patients in countries in Europe where it is available, but less inclined to switch patients already taking the brand. The company’s experience in Europe could offer lessons for manufacturers looking to bring biosimilars to market in the US.
Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway
Biosimilar products are not intended to be stand-alone development programs, agency stresses, noting that early analytical data can allow for more targeted clinical trials later.
US FDA Formalizes ‘One-Trial’ Approach For Oncology Accelerated Approval
Draft guidance gives recommendations for conducting one randomized controlled trial to generate the evidence for accelerated approval and confirm clinical benefit.